Professor Volker Schirrmacher vom Kölner IOZK eröffnet die Tagung an der Universität zu Kiel mit seinem Vortrag zur Erforschung onkolytischer Viren im Zusammenhang der individuellen Krebs-Immuntherapie.

Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy

From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)

International Journal of Oncology: „Von der Chemotherapie zur biologischen Therapie“, Prof. Dr. Volker Schirrmacher

Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group